SHINE Technologies

SHINE Technologies, formerly SHINE Medical Technologies, is a nuclear technology company committed to improving the lives of people and the planet.

SHINE designs, manufactures and operates innovative fusion systems for near-term applications like producing medical isotopes and inspecting industrial components.

SHINE was founded in 2010 by Greg Piefer. The company has its headquarter based in Janesville, Wisconsin, with its European headquartered based in Veendam, the Netherlands.

 

SHINE's systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99.

 

SHINE is deploying and scaling fusion technology in a four-phased approach to solve today’s problems in medicine, manufacturing and nuclear waste recycling, with the final goal of achieving safe, clean, abundant fusion energy. Now in its second phase, SHINE is creating critical medical isotopes used to diagnose and treat life-threatening diseases in patients across the globe.

 

SHINE announced a new service providing state-of-the-art radiation effects testing. SHINE’s radiation effects testing, called FLARE (Fusion Linear Accelerator for Radiation Effects), is expected to provide the industry’s highest fluence of high-energy fusion neutrons (referred to as 14 MeV).

 

SHINE is backed by Koch Disruptive Technologies (KDT), Baillie Gifford, Fidelity Management and Research Company, Oaktree Capital Management, Deerfield Management Company, and others. The company raised $150M in Series C-5 round on Jun 28, 2021. This brings SHINE's total funding to $672.2M to date.

 

 

  • Year founded: 2010
  • Funding Info: $672.2M over 11 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: NA
  • City/Town: Janesville
  • State: Wisconsin
  • Country: United States
Related businesses